Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population

Weijia Li; Adarsh Katamreddy; Rachna Kataria; Merle L Myerson; Cynthia C Taub

doi:10.1007/s40801-021-00277-0

Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population

Drugs Real World Outcomes. 2022 Mar;9(1):53-62. doi: 10.1007/s40801-021-00277-0. Epub 2021 Sep 3.

Authors

Weijia Li¹, Adarsh Katamreddy¹, Rachna Kataria², Merle L Myerson³, Cynthia C Taub^{4

5}

Affiliations

¹ Department of Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, The Bronx, NY, USA.
² Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, The Bronx, NY, USA.
³ Section of Cardiovascular Medicine, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, 1 Medical Center Drive, Lebanon, NH, 03756, USA.
⁴ Division of Cardiology, Montefiore Medical Center/Albert Einstein College of Medicine, The Bronx, NY, USA. cynthia.c.taub@hitchcock.org.
⁵ Section of Cardiovascular Medicine, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, 1 Medical Center Drive, Lebanon, NH, 03756, USA. cynthia.c.taub@hitchcock.org.

Abstract

Background: Limited evidence-based therapies exist for the management of heart failure with preserved ejection fraction (HFpEF). Sodium-glucose cotransporter-2 inhibitor (SGLT2i) use in patients with systolic heart failure (HFrEF) and type-2-diabetes mellitus (T2DM) is associated with improved cardiovascular (CV) and renal outcomes.

Objective: We sought to examine whether there is an association of SGLT2i use with improved CV outcomes in patients with HFpEF.

Patients and methods: We conducted a single-center, retrospective review of patients with HFpEF and T2DM. The cohort was divided into two groups based on prescription of a SGLT2i or sitagliptin. The primary outcome was heart failure hospitalization (HFH); secondary outcomes were all-cause hospitalization and acute kidney injury (AKI).

Results: After propensity score matching, there were 250 patients (89 in the SGLT2i group, 161 in the sitagliptin group), with a mean follow-up of 295 days. Univariate Cox regression analysis showed that the SGLT2i group had a reduced risk of HFH versus the sitagliptin group (hazard ratio (HR) 0.13; 95% confidence interval (CI) (0.05-0.36); p < 0.001). The SGLT2i group had a decreased risk of all-cause hospitalization (HR 0.48; 95% CI (0.33-0.70); p < 0.001) and SGLT2i had a lower risk of AKI (HR 0.39; 95% CI (0.20-0.74); p = 0.004).

Conclusions: The use of SGLT2is is associated with a reduced incidence of HFH and AKI in patients with HFpEF and T2DM.